» Articles » PMID: 15517888

Immunocytochemical and Pharmacological Characterisation of P2-purinoceptor-mediated Cell Growth and Death in PC-3 Hormone Refractory Prostate Cancer Cells

Overview
Journal Anticancer Res
Specialty Oncology
Date 2004 Nov 3
PMID 15517888
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Extracellular nucleotides (e.g adenosine 5'-triphosphate, ATP) influence biological processes via purinergic receptors. We characterised the P2-purinoreceptors in human hormone refractory prostate cancer (HRPC) cells (PC-3 cells).

Results: 1. Immunofluorescent staining demonstrated P2X3 P2X, P2X5 P2X7 and P2Y2 receptors. 2. ATP inhibited cell growth by up to 91% over 72h. Pharmacological characterisation indicated a P2X-purinoreceptor-mediated response. 3. Comparable maximum growth inhibition was seen after either a single addition of 1mM or daily addition of 100mM ATP. ATP concentrations ([ATP]) returned to baseline levels within 24h if the initial [ATP] was < or =100 HM, while [ATP] remained high for 72h if a single concentration of 1 mM was used. 4. ATP 1 mM significantly (p<0.001) increased the proportion of cells undergoing apoptosis from 0.27% (+/- 0.04%) to 5.28% (+/- 0.77%).

Conclusion: Threshold concentrations of ATP inhibited HRPC cell growth in vitro via the activation of P2X-purinoreceptors. The role of nucleotides in the treatment of HRPC requires further investigation.

Citing Articles

The P2 purinoceptors in prostate cancer.

Wang Z, Zhu S, Tan S, Zeng Y, Zeng H Purinergic Signal. 2022; 19(1):255-263.

PMID: 35771310 PMC: 9984634. DOI: 10.1007/s11302-022-09874-2.


Autocrine and paracrine purinergic signaling in the most lethal types of cancer.

Reyna-Jeldes M, Diaz-Munoz M, Madariaga J, Coddou C, Vazquez-Cuevas F Purinergic Signal. 2021; 17(3):345-370.

PMID: 33982134 PMC: 8410929. DOI: 10.1007/s11302-021-09785-8.


P2Y receptors for extracellular nucleotides: Contributions to cancer progression and therapeutic implications.

Woods L, Munoz Forti K, Shanbhag V, Camden J, Weisman G Biochem Pharmacol. 2021; 187:114406.

PMID: 33412103 PMC: 8096679. DOI: 10.1016/j.bcp.2021.114406.


Synthesis and preclinical validation of novel P2Y1 receptor ligands as a potent anti-prostate cancer agent.

Le H, Rimpilainen T, Konda Mani S, Murugesan A, Yli-Harja O, Candeias N Sci Rep. 2019; 9(1):18938.

PMID: 31831761 PMC: 6908675. DOI: 10.1038/s41598-019-55194-8.


P2Y2 purinergic receptor modulates virus yield, calcium homeostasis, and cell motility in human cytomegalovirus-infected cells.

Chen S, Shenk T, Nogalski M Proc Natl Acad Sci U S A. 2019; 116(38):18971-18982.

PMID: 31481624 PMC: 6754545. DOI: 10.1073/pnas.1907562116.